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Background: The Oral Health Impact Profile-14 (OHIP-14) was designed to assess patients’ perception of the 
impact of oral disorders on their quality of life (QoL). Although the OHIP-14 is now frequently used in patients 
with head and neck cancer, data related to its measurement properties in this population are scarce. The aim of 
the present study was to evaluate the reliability and validity of the OHIP-14 in a sample of Serbian patients with 
head and neck cancer.
Material and Methods: Data were available for 345 patients (257 [74.5%] males; aged 30-92 years), with head and 
neck cancer. All patients completed the OHIP-14 and the European Organization for Research and Treatment of 
Cancer (EORTC) QLQ-C30 and QLQ-H&N35. Factor analyses, internal consistency reliability (i.e., Cronbach’s α 
coefficient), and construct validity were analyzed.
Results: The factor analyses confirmed that 14 OHIP items were measuring a single underlying factor. Cronbach’s 
α coefficient was 0.98 and corrected item-total correlations ranged 0.77-0.93. Lower OHIP-14 scores (i.e., lower 
impacts on oral health) were more frequently present among patients who had only surgery as a therapeutic pro-
cedure compared to those who had surgery accompanied with radio- and chemotherapy (p < 0.01). Patients with 
a tumor stage 0-II also had lower OHIP-14 scores compared to those who had a tumor stage III-IV (p < 0.01). The 
OHIP-14 correlated significantly with the QLQ-C30 and QLQ-H&N35 scales.
Conclusions: As a unidimensional instrument, the OHIP-14 provides oral QoL assessments with sound internal 
consistency reliability and construct validity among patients with head and neck cancer.
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Introduction
Over the past 30 years, patient reported outcome (PRO) 
measures have become standard methods for provid-
ing additional information on how patients perceive 
the impacts of their health condition and its treatment 
on everyday living (1). Especially, significant research 
attention has been placed to develop PROs that would 
assess comprehensively survival and living of people 
with cancer, such as symptoms and side effects, limita-
tions, well-being, functioning, health-related quality of 
life (QoL).
Head and neck cancer (HNC) affect different locations 
of the head and neck (2), with physical (e.g., appear-
ance changes or pain) and functional alternations (e.g., 
changes in mastication, deglutition or phonation), but 
also multiple psychosocial consequences (e.g., anxiety, 
depression or social functioning) (2-5). Antineoplastic 
treatments such as surgery, chemo- and radiotherapy 
usually result in multiple adverse effects and squeals, 
too (5). Thus, measuring the impacts of their health con-
dition and its treatment via PROs is now used in many 
research studies, clinical trials, and clinical settings in 
patients with HNC.
The oral health of patients with HNC can significantly 
deteriorate due to the conduction itself and antineoplas-
tic treatments, including mentioned physical conditions 
and functional changes (6). Oral QoL, as an internation-
ally accepted concept to assess how patients are affected 
by oral conditions and how they experience the effect of 
prescribed interventions (7), has been recognized as an 
important PRO among patients with HNC, too. Among 
the first, Shavi et al. (8) demonstrated a high impact of 
the oral health on the QoL of patients with HNC, which 
was confirmed in later studies (6,9-11). In particular, 
studies showed that patients with HNC who had been 
treated surgically alone had better QoL compared to the 
combined treatment modalities (10) and the oral health 
condition of these patients deteriorates after radiothera-
py, with direct impacts on their QoL (6).
The Oral Health Impact Profile (OHIP) is designed 
to assess individuals’ perception of the impact of oral 
disorders on their QoL (12). This is a 49-item instru-
ment assessing dysfunction, discomfort, disability, and 
handicap associated with oral disorders/conditions and 
their treatments. A short form, the OHIP-14, was de-
veloped to represent the main domains of the original, 
namely functional limitation, physical pain, psychologi-
cal discomfort, physical, psychological and social dis-
ability, and overall handicap (13), and it is frequently 
used for oral QoL assessments. Available studies dem-
onstrated sound psychometric properties of the OHIP-
14 in different populations including different language 
versions (14-23). Nevertheless, although the OHIP-14 is 
more and more used in patients with HNC (6,9-11), data 
related to its psychometric properties in this population 
are scarce. Good internal consistency (Cronbach’s α = 
0.86) was reported in one study with the Brazilian ver-
sion (9). Data related to different aspects of validity are 
missing. Therefore, the aim of the present study was to 
evaluate the reliability and validity of the OHIP-14 in a 
sample of Serbian patients with HNC, including the di-




This is a cross-sectional, psychometric study that in-
cluded patients treated for HNC, who were admitted 
to Department of ENT with maxillofacial surgery of 
Clinical Hospital Centre Zemun, Belgrade, Serbia. As a 
sample of convenience, all patients were recruited dur-
ing pre-scheduled assessments when visiting a doctor 
for follow-up care. The participation was on a voluntary 
basis and the only exclusion criterion was inability to 
read and/or write. To all patients was first explained the 
aim of the study and all included patients provided writ-
ten informed consent before participating in the study. 
The instruments (see below) were self-completed by in-
cluded patients.  
Complete data for analyses were available for 345 pa-
tients with HNC (257 [74.5%] males), aged 30-92 years 
(Table 1).
- Instruments
OHIP-14: The OHIP-14 has 14 items with answers rated 
on a 5-point Likert scale (from 1 = never to 5 = very 
often) to indicate a level of different problems related 
to oral health over in the last 12 months (13). The total 
score is the sum of all answered items and it can range 
from 0 to 56. The higher the score, the worse the impact 
on oral health is. The Serbian version was developed 
in an earlier study (24), and adapted by the one of the 
author of this study, and it has the same format and con-
tents as the original.
European Organization for Research and Treatment of 
Cancer (EORTC) QLQ-C30 and QLQ-H&N35: The 
QLQ-C30 is a 30-item, cancer-specific instrument for 
QoL assessments (25). It has the following multi-item 
function/symptom scales: Global health/QoL, Physical, 
Role, Emotional, Cognitive, and Social functioning, Fa-
tigue, Nausea and vomiting, Pain, Dyspnea, Insomnia, 
Appetite loss, Constipation, Diarrhea, and Financial 
difficulties. As a supplementary module, the QLQ-
H&N35 is a 35-item instrument for the assessments of 
symptoms associated specifically with HNC (26). It has 
the following symptom scales: Pain in the mouth, Swal-
lowing, Senses, Speech, Trouble with social eating, 
Trouble with social contact, Sexuality, Problems with 
teeth, Problems opening mouth, Dry mouth, Sticky sa-
liva, Coughing, Felt ill, Painkillers, Nutritional supple-
ments, Feeding tube, Weight loss, and Weight gain.
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Scores for all scales of the both instruments are calcu-
lated by linear transformation of raw scores into a 0–100 
score, where scores of 100 represent the best outcomes 
on the QLQ-C30 functioning scales and the worst out-
comes on the QLQ-C30 and QLQ-H&N35 scales. The 
Serbian versions were provided by the EORTC Group.
- Statistical analysis
Statistical analyses included the assessment of descrip-
tive characteristics, factor structure (i.e., exploratory 
factor analysis [EFA] and confirmatory factor analysis 
[CFA]), internal consistency reliability, and construct 
validity (i.e., know-group and convergent/discriminant 
validity). To carry out the analyses, SPSS Statistics Ver-
sion 24 and AMOS Version 18 were used.
Factor structure: To explore the factor structure (i.e., 
EFA and CFA), the whole sample was randomly split. 
Principal axis factoring (PAF) with Promax (oblique) 
extraction method, as an EFA method, was used with 
the data of 162 participants (one half of the sample). 
Afterwards, 14 items were subjected to a maximum 
likelihood solution with the second sample of 183 par-
ticipants (the other half) was employed to test CFA. A 
series mean repletion was used to handle missing data 
as the amount was negligible per item (0.3–0.9%). Ab-
solute model fit to the data for the CFA was evaluated 
using the comparative fit index (CFI), Tucker-Lewis in-
dex (TLI), and root mean square error of approximation 
(RMSEA) with the following cut-offs (27): TLI and CFI 
≥ .90, RMSEA ≤ .08 as adequate; TLI and CFI ≥ .95, 
RMSEA ≤ .06 as good fit; RMSEA ≤ .10 as marginal fit.
Descriptives and internal consistency reliability: The 
distribution of mean scores, standard deviation (SD), 
and percentage floor and ceiling effects were calculated. 
A floor and ceiling effect were defined as the percentage 
of individuals with the best and worst results respect-
fully. More than 15% of participants with the highest 
or lowest score on one particular scale were considered 
as a relevant effect. Internal consistency reliability was 
evaluated using Cronbach’s α coefficient and the values 
of α ≥ 0.7 were considered acceptable.
Table 1: Characteristics of studied patients (n = 345).
Gender, n (%) 257 (74.5) male
88 (25.5) female
Age (M, SD) years, range 69.65 (11.04), 30-92
Educational level, n (%) 61 (17.7) elementary school
231 (67.0) high school
53 (15.3) college/university 
Employment status, n (%) 91 (26.4) employed 
31 (9) unemployed
223 (64.6) retired 
Relationship status, n (%) 224 (64.9) in a relationship
121 (35.1) not in a relationship 
Alcohol drinking, n (%) 309 (89.6) once to twice per month or less 
36 (10.4) once or more per week
Smoking, n (%) 248 (71.9) no
61 (17.7) yes, sometimes
36 (10.4) yes, daily 
Comorbidity, n (%) 325 (94.2) one or more comorbidities 
20 (5.8) no comorbidity 
Age when diagnosed (M, SD) years, range 69.19 (11.14), 29-92
Time since diagnosed 100 (29.0) < one month
140 (40.6) one to 12 months 
105 (30.4) > 12 months 
Location of primary tumor 100 (29.0) larynx  
155 (44.9) oral cavity and/or pharynx (epi-, oro-, hypo-pharynx)
90 (26.1) other  
TNM stage, n (%) 236 (68.4) 0-II109 (31.6) III-IV
Type of treatment
176 (51.0) surgery only 
113 (32.8) surgery with radiotherapy
13 (3.8) surgery with chemotherapy
43 (12.4) surgery with radio- and chemotherapy
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Know-group validity: A t-test and one-way analysis of 
variance (ANOVA) were used to test for differences in 
OHIP-14 scores among different groups for which it 
would be expected that OHIP-14 scores differ. It was 
hypothesized that patients with cancer located other-
then-oral regions would have lower scores (i.e., lower 
impacts on oral health) then those with oral cavity and 
pharyngeal cancer (epi/oro/hypo pharynx) or laryngeal 
cancer as well as those patients who had only surgery 
as a therapeutic procedure compared to those who had 
surgery accompanied with radio- and chemotherapy pa-
tients, and patients with a TNM stage 0-II compared to 
a TNM stage III-IV.
Convergent/discriminant validity: Convergent and dis-
criminant validity was evaluated with Pearson correla-
tion coefficients between the OHIP-14 and the QLQ-
C30 and QLQ-H&N35 scales. Correlation coefficients 
ranging 0.1–0.3 were considered low, those 0.31–0.5 
moderate, and those exceeding 0.5 high.
Results
- Factor Structure
The appropriateness for conducting the EFA was 
confirmed by the results of the Kaiser–Meyer–Olkin 
Measure of Sampling Adequacy (KMO = 0.96) and 
Bartlett’s Test of Sphericity (χ2 (df) = 3286.54 [91], p 
< 0.01). The PAF analysis revealed a single underly-
ing factor explaining 79.7% of the total variance, with 
all 14 items having high factor loadings (ranging 0.66-
0.95). Afterwards, a CFA analysis of model showed 
the following fit indexes (χ2 (df) = 285.49 [77]; TLI 
= 0.93, CFI = 0.94, and RMSEA = 0.12, with all stan-
dardized regression weights being statistically signifi-
cant (ranging 0.63-0.95; p < 0.01). On the same sample 
was also tested the model of seven correlated factors 
(15,16) with the following fit indexes obtained: χ2 (df) 
= 174.14 [56]; TLI = 0.94, CFI = 0.97, and RMSEA = 
0.11. In addition, the model with three correlated fac-
tors proposed by Zucoloto et al. (23) was also tested 
and the following fit indexes were obtained: χ2 (df) = 
254.81 [74]; TLI = 0.94, CFI = 0.95, and RMSEA = 
0.12.
- Internal consistency reliability
For the total sample Cronbach’s α coefficient was 0.98 
and corrected item-total correlations ranged 0.77-0.93. 
Cronbach’s α coefficient was > 0.92 for five groups of 
patients (Table 2). The percentages of patients having 
the highest or lowest OHIP score were < 4 indicating on 
the absence of floor and ceiling effects.
- Known-group validity
Patients who had only surgery as a therapeutic proce-
dure had significantly lower OHIP-14 scores compared 
to those patients who had surgery accompanied with ra-
dio- and chemotherapy (t (df) = -15.99 [343]; p < 0.01). 
In addition, patients with a TNM stage 0-II had signifi-
cantly lower OHIP-14 scores compared to those who 
had a TNM stage III-IV (t (df) = 11.05 [343]; p < 0.01). 
Based on ANOVA, statistically significant differences 
in the OHIP-14 score were found when comparing pa-
tients with three different localizations of cancer (F [2, 
342] = 22.63, p < 0.01; Table 2). As predicted, patients 
with laryngeal and with oral cavity and pharyngeal 
carcinoma had significantly higher scores compared to 
those with cancer located on the other sites of the head 
and neck (p < 0.01).
- Convergent/Discriminant Validity
Except with the Teeth (r = 0.29), Diarrhea (r = 0.22), 
and Weight gain (r = -0.27) scale, the OHIP-14 corre-
lated moderately to highly with the other QLQ-C30 and 
QLQ-H&N35 scales (Table 3).
Mean (SD) Range % Floor % Ceiling Cronbach’s α
Therapeutic procedure
Surgery only, n = 176 15.25 (9.54) 0-42 4.0 0.6 0.96
Surgery with radio- and chemotherapy, n = 169 33.73 (11.84) 0.52 0.6 0.6 0.97
TNM stage
0-II, n = 236 19.38 (12.34) 0-49 3 1.3 0.97
III-IV, n = 109 34.95 (11.81) 1-52 0.9 0.9 0.97
Cancer localization
Larynx, n = 100 27.48 (15.44) 0-51 1 1 0.92
Oral cavity and/or pharynx, n = 155 26.97 (14.15) 0-52 1.9 0.6 0.98
Other, n = 90 16.18 (8.45) 0-34 3.3 1.1 0.95
Total, n = 345 24.30 (14.15) 0-52 2 0.3 0.98
Table 2: Main descriptive statistics of OHIP-14 scores.
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Discussion
The OHIP-14 was developed as short instrument to rep-
resent functional limitation, physical pain, psychologi-
cal discomfort, physical, psychological and social dis-
ability, and overall handicap in relation to oral disorders 
(13). Available psychometric studies showed that its 14 
items are best representing either one single underlying 
factor (15), three correlated factors (15,23), or seven cor-
related factors (13-16) of oral health. The results of our 
factor analyses indicate that all 14 items explain sub-
stantial proportion of the variance in oral health as one 
factor and this model was generally confirmed in the 
CFA, donating on the unidimensionality of the instru-
ment. The results of the CFA showed that the model of 
three and seven correlated factors had minimally higher 
fit indexes in comparison to the one factor model, with 
the RMSEA remaining practically the same; marginal. 
In addition, sound internal consistency of the total score 
of 14 items, high Cronbach’s coefficients and high cor-
rected item-total correlations as previously reported 
(13-23), indicate similar co-variances between the items 
and high homogeneity when used in a one single score. 
Thus, together our data for factor analyses and internal 
consistency indicate that the OHIP-14 for patients with 
HNC is best to be used as a unidimensional instrument, 
which is in line with previous data with other popula-
tions (15).
Further analyses showed that the OHIP-14 has appro-
priate aspects of construct validity, namely known-
group and convergent/discriminant validity, what is 
also in line with the previous findings from studies 
with other populations (14,20,23). Based on the results 
of the t-test and ANOVA, OHIP-14 scores were likely 
linked to expected levels of compromised oral health 
due to the condition or therapeutic procedures, in such 
a way that an OHIP-14 score would be higher if oral 
health is more compromised and vice versa. In addi-
tion, the OHIP-14 correlated moderately to highly with 
the QLQ-C30 functioning and its theoretically similar 
symptom scales and the QLQ-H&N35 scales, indicating 
that the lower the functioning and higher the symptoms 
are, the greater the OHIP-14 score is (i.e., sound conver-
gent validity). Lower correlations of the OHIP-14 with 
the scales Dyspnea, Constipation, Diarrhea, Pain kill-
ers, Nutritional supplements, Feeding tube, and Weight 
gain donate on sound discriminant validity. However, 
of particular importance are correlation with the QLQ-
H&N35 scales Pain, Swallowing, Senses problems, 
Speech problems, Trouble with social eating, Trouble 
with social contact, Opening mouth, Dry mouth, and 
Sticky saliva, which were high, indicating on the over-
lapping of the measuring construct of the OHIP-14 with 
the measuring aspects of these scales. In this regard, the 
use of OHIP-14 could replace the QLQ-H&N35, at least 
the mentioned scales, in patients with HNC especially 
when it comes to measure oral health or oral QoL as one 
general indicator (i.e., one score).
There are some limitations to be acknowledged regard-
ing the methodology of our study. It should be noted that 
only patients who agreed to participate were included 
and the sampling was convenient, thus those who may 
have less or more advanced cancer stages might not 
have participated. Additional psychometric aspects, 
such as screening properties, test-retest, responsiveness 
or predictive validity, and diagnostic value were also 
not tested.
QLQ-C30 scales M (SD)* r QLQ-H&N35 scales M (SD)* r
Global health/QoL 41.74 (23.88) -0.75 Pain in the mouth 23.76 (16.91) 0.85
Physical functioning 66.16 (20.42) -0.67 Swallowing 23.54 (20.73) 0.85
Role functioning 51.30 (29.59) -0.69 Senses problems 19.32 (22.70) 0.74
Emotional functioning 71.06 (19.86) -0.79 Speech problems 31.88 (31.49) 0.76
Cognitive functioning 63.86 (18.24) -0.51 Trouble with social eating 38.22 (28.98) 0.89
Social functioning 47.01 (30.06) -0.73 Trouble with social contact 39.94 (29.33) 0.74
Fatigue 46.41 (20.56) 0.70 Less sexuality 60.38 (27.79) 0.64
Nausea and vomiting 12.74 (18.91) 0.61 Problems with teeth 5.31 (13.47) 0.29
Pain 30.77 (11.67) 0.47 Problems opening mouth 23.74 (20.08) 0.65
Dyspnoea 15.36 (17.39) 0.45 Dry mouth 35.07 (21.48) 0.62
Insomnia 32.37 (29.84) 0.56 Sticky saliva 38.55 (22.84) 0.64
Appetite loss 36.91 (37.82) 0.79 Coughing 19.13 (19.55) 0.61
Constipation 13.91 (22.14) 0.49 Felt ill 40.96 (26.10) 0.74
Diarrhea 4.64 (14.07) 0.22 Painkillers 83.18 (37.45) 0.47
Financial difficulties 44.83 (30.28) 0.60 Nutritional supplements 47.82 (50.03) 0.47
Feeding tube 7.24 (25.96) 0.38
Weight loss 58.55 (49.33) 0.67
Weight gain 9.03 (28.71) -0.27
*The mean (SD) value of a scale score.
Table 3: Correlations (r) of the OHIP-14 with the QLQ-C30 and QLQ-H&N35 scales.
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Summarizing, the OHIP-14 is measuring a single un-
derlying factor of oral health among patients with HNC, 
with sound internal consistency and construct validity. 
This study generalizes its use and opens the space for 
further use of OHIP-14 with these patients in research 
and clinical setting.
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